Patients on this protocol commonly report better energy and clearer thinking
For example, statins have been implicated in directly causing immune-mediated necrotizing myopathy thought to be caused by upregulation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the molecular target of statins, resulting in presentation of highly immunogenic HMGCR peptides by human leukocyte antigens
Semaglutide Dose Ranges and Weight Loss Outcomes Research from the STEP clinical trials demonstrated that weekly semaglutide doses of 0.5 mg, 1.0 mg, and 2.4 mg produced dose-dependent weight loss, with average reductions ranging from 5% to 18% of baseline body weight over 68 weeks
however, the long-term impact on CV outcomes was inconclusive [7]
Supports weight loss
Refer to the Dosage Chart: Begin treatment by following a compounded Semaglutide dosage chart , which outlines dosage progression over weeks to ensure safety and effectiveness